Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 11/20 | 0.44 |
| ▸ | P2RX2 | Q9UBL9 | 11/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | ITK | Q08881 | 2/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2760641 | 0.92 | NR1I2 (0.46) | NR1I2CYP2C9SCN5ASCN9AADORA2A | |
| SCHEMBL12757539 | 0.90 | SCN5A (0.49) | SCN5ASCN9AADORA2ANAMPTITK | |
| SCHEMBL1495384 | 0.89 | NR1I2 (0.44) | NR1I2CYP2C9SCN5ASCN9AP2RX3 | |
| SCHEMBL1495389 | 0.89 | NR1I2 (0.44) | NR1I2CYP2C9SCN5ASCN9AP2RX3 | |
| SCHEMBL1495425 | 0.88 | P2RX3 (0.48) | P2RX3P2RX2 | |
| SCHEMBL12757587 | 0.86 | HCRTR1 (0.47) | P2RX3P2RX2PRKAA2 | |
| SCHEMBL1495724 | 0.86 | P2RX3 (0.57) | P2RX3P2RX2 | |
| SCHEMBL7996726 | 0.86 | SCN5A (0.45) | SCN5ASCN9AADORA2ANAMPTITK | |
| SCHEMBL1495683 | 0.84 | P2RX3 (0.46) | SCN5ASCN9AADORA2AP2RX3P2RX2 | |
| SCHEMBL12757607 | 0.82 | NR1I2 (0.50) | NR1I2CYP2C9P2RX3P2RX2ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262766-B1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2015-11-11 | — | — | EP | claimed |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | RENOVIS, INC. | 2015-09-24 | — | — | US | claimed |
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-03-17 | — | — | US | claimed |
| EP-2262766-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | Renovis, Inc. (US) | 2010-12-22 | — | — | EP | claimed |
| WO-2009110985-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2009-09-11 | — | — | WO | claimed |
| EP-2262766-B1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2015-11-11 | — | — | EP | disclosed |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | RENOVIS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | RENOVIS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | RENOVIS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-8946439-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946439-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946439-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-03-17 | — | — | US | disclosed |
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-03-17 | — | — | US | disclosed |
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | IL1B, ADORA2B, AVPR1B | NR1I2 461/4885CYP2C9 1604/4885SCN5A 3448/4885 |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | IL1B, ADORA2B, AVPR1B | NR1I2 461/4885CYP2C9 1604/4885SCN5A 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.